Guopan Yu
Guangdong Second Provincial General Hospital · Nanfang Hospital, Southern Medical University
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Guopan Yu as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-11 16:06 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT07813390 · Homoharringtonine, Lisaftoclax, and Azacitidine for AML After Venetoclax-Based Therapy FailureGuangdong Second Provincial General Hospital · enrolling by invitation · Acute Myeloid Leukemia (AML) · principal investigator
- Ph3NCT06810791 · HVA vs IA/DA or VA in the Treatment of ND HR-AMLNanfang Hospital, Southern Medical University · recruiting · Newly Diagnosed Acute Myeloid Leukemia With High Risk · principal investigator
- Ph4NCT06763666 · CLAG+VEN vs CLAG in the Treatment of Relapsed/Refractory AMLNanfang Hospital, Southern Medical University · not yet recruiting · Relapsed/Refractory AML · principal investigator
- Ph2/Ph3NCT03642236 · Combination of BTK Inhibitor Overcomes Drug-resistance in Refractory/Relapsed FLT3 Mutant AMLNanfang Hospital, Southern Medical University · unknown · FLT3-ITD Mutation, Acute Myeloid Leukemia, Brutons Tyrosine Kinase · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-11 16:06 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-11 16:06 UTC. The ranking covers the 200 most relevant of 220 PubMed records, and a shared surname and initials can bring in a namesake. All 220 on PubMed
- 869 citationsRCR 46.7
- 447 citationsRCR 14.4
- Two Phase 3 Trials of Baricitinib for Alopecia Areata.N Engl J Med · 2022410 citationsRCR 38.3
- 406 citationsRCR 24.7
- 392 citationsRCR 42.0
- Tislelizumab Versus Chemotherapy as Second-Line Treatment for Advanced or Metastatic Esophageal Squamous Cell Carcinoma (RATIONALE-302): A Randomized Phase III Study.J Clin Oncol · 2022291 citationsRCR 18.2
- Serum miR-146a and miR-223 as potential new biomarkers for sepsis.Biochem Biophys Res Commun · 2010270 citationsRCR 7.3
- Open-label, Multicenter, Phase II Study of RC48-ADC, a HER2-Targeting Antibody-Drug Conjugate, in Patients with Locally Advanced or Metastatic Urothelial Carcinoma.Clin Cancer Res · 2021256 citationsRCR 14.2
- Laparoscopic versus open pancreatoduodenectomy for pancreatic or periampullary tumours: a multicentre, open-label, randomised controlled trial.Lancet Gastroenterol Hepatol · 2021230 citationsRCR 17.0
- Efficacy and safety of a novel anti-HER2 therapeutic antibody RC48 in patients with HER2-overexpressing, locally advanced or metastatic gastric or gastroesophageal junction cancer: a single-arm phase II study.Cancer Commun (Lond) · 2021185 citationsRCR 9.8